pemigatinib
innovent biologics,incyte
['pemazyre', 'pemigatinib', 'innovent']
innovent announces overall survival results of phase 2 study of pemazyre (pemigatinib) in chinese patients with advanced cholangiocarcinoma presented at aacr annual meeting 2023 
To develop and commercialize high-quality biopharmaceuticals that are affordable to ordinary people.